Clinical Trial: Safety and Feasibility of Endovascular Cooling Device in Patients with Hypothermic Cardiopulmonary Resuscitation
This study is currently recruiting patients.
Verified by National Taiwan University Hospital January 2004
| Sponsored by: | National Taiwan University Hospital | | Information provided by: | National Taiwan University Hospital | | ClinicalTrials.gov Identifier: | NCT00154674 | |
Purpose
Hypothermic resuscitation is proven to be benefit to the
cardiac origin
cardiac arrest patients for it improve brain recovery dramatically. However, traditional cooling devices and methods, most external cooling methods, include ice blanket, cooling helmet, or ice packing lower the body temperature slowly or ieefficiently which make many emergency physicians hesitate perfomed hypothermic resuscitation. To improve and promote the practice of hypothermia resuscitation, more efficient temperature control method is necessary. We conduct this
clinical trial to evaluate the safety and feasibility of internal cooling
catheter and temperature regulatory device , which is provened by FDA in
neurologic ICU for temperature control, in the
cardiac arrest patients.
| Condition | Intervention |
Cardiac Arrest
| Device: ICY catheter, Thermoguard device
|
MedlinePlus related topics: Heart Diseases
Study Type: Interventional
Study Design: Treatment, Non-Randomized, Open Label, Historical Control, Single Group Assignment
Further Study Details:
Primary Outcomes: complications and feasibility of endovascular cooling device
Expected Total Enrollment: 15
Study start: April 2005; Expected completion: March 2006
Last follow-up: October 2005; Data entry closure: March 2006
We recrude successful resuscitated nontraumatic
cardiac arrest adult patients in the emergency department to evaluate the safety and feasibility of application those invasive internal temperature regulater devices. Internal cooling catheter," ICY" , and thermal regulator device, " Coolguard 2000 " are applied to the patients from femoral vein. WE definite 4 stages according to the temerature during the
clinical trial: The Cooling Phase" " Hypothermia phase" " Rewarming phase" and " Postrewarming phase" . The temperature is lowed or elevated by the rate 0.5C/hr during the Cooling and Rewarming Phase , and it is maintained 33 +/- 1 C during hypothermia phase for 12 hours according to the comment of ACLS.To understand the safety and feasibility, regular
blood sampling, bedside EEG and
vital monitors, and special sheets are designed to document the every reasons,time points or every
clinical events during hypothermia therapy. The patients is observed untilled rewarming finish for 48 hours or till death if expired during post-resuscitation hypothermia therapy.
Eligibility
Ages Eligible for Study: 18 Years - 78 Years, Genders Eligible for Study: Both
Criteria
Inclusion Criteria:
- Non-traumatic collapsed patients, whose pulsation continues and persists more than 5 minutes after return of spontaneous circulation from cardiopulmonary resuscitation and consciousness level is less than GCS 5 points.
Exclusion Criteria:
- 1. Age > 78 y/o or < 18 y/o 2. Core temperature< 34℃or > 38 ℃ after resuscitation 3. Pregnancy 4. Underline terminal malignancy disorder or refuse aggressive treatment cancer patient 5. Massive bleeding, known coagulopathy, or received regular anticoagulant medication 6. Persisted hypotension ( mean arterial BP < 60 mmHg) after resuscitation even under inotropic agents 7. No bed available in ICU
Location and Contact Information
Please refer to this study by ClinicalTrials.gov identifier NCT00154674
Chiung Yuan Hsu, MD 886-2-23123456 Ext. 2831 dtemer01@yahoo.com.tw
Wen Jone Chen, PHD 886-2-23123456 Ext. 2831 jone@ha.mc.ntu.edu.tw
Taiwan NTUH, Taipei, 100, Taiwan; Recruiting
Chiung Yuan Hsu, MD 886-2-23123456 Ext. 5926 dtemer01@yahoo.com.tw
Study chairs or principal investigators
Wen Jone Chen, PHD, Principal Investigator, NTUH
More Information
Study ID Numbers: 25MD03
Last Updated: September 9, 2005
Record first received: September 8, 2005
ClinicalTrials.gov Identifier: NCT00154674
Health Authority: Taiwan: Department of Health
ClinicalTrials.gov processed this record on 2005-09-13
Source: ClinicalTrials.gov
Cache Date: September 14, 2005